» Articles » PMID: 19187092

L-DOPA Activates ERK Signaling and Phosphorylates Histone H3 in the Striatonigral Medium Spiny Neurons of Hemiparkinsonian Mice

Overview
Journal J Neurochem
Specialties Chemistry
Neurology
Date 2009 Feb 4
PMID 19187092
Citations 88
Authors
Affiliations
Soon will be listed here.
Abstract

In the dopamine-depleted striatum, extracellular signal-regulated kinase (ERK) signaling is implicated in the development of L-DOPA-induced dyskinesia. To gain insights on its role in this disorder, we examined the effects of L-DOPA on the state of phosphorylation of ERK and downstream target proteins in striatopallidal and striatonigral medium spiny neurons (MSNs). For this purpose, we employed mice expressing enhanced green fluorescent protein (EGFP) under the control of the promoters for the dopamine D(2) receptor (Drd2-EGFP mice) or the dopamine D(1) receptor (Drd1a-EGFP mice), which are expressed in striatopallidal and striatonigral MSNs, respectively. In 6-hydroxydopamine-lesioned Drd2-EGFP mice, L-DOPA increased the phosphorylation of ERK, mitogen- and stress-activated kinase 1 and histone H3, selectively in EGFP-negative MSNs. Conversely, a complete co-localization between EGFP and these phosphoproteins was observed in Drd1a-EGFP mice. The effect of L-DOPA was prevented by blockade of dopamine D(1) receptors. The same pattern of activation of ERK signaling was observed in dyskinetic mice, after repeated administration of L-DOPA. Our results demonstrate that in the dopamine-depleted striatum, L-DOPA activates ERK signaling specifically in striatonigral MSNs. This regulation may result in ERK-dependent changes in striatal plasticity leading to dyskinesia.

Citing Articles

The Interaction of Histamine H and Dopamine D Receptors on Hyperkinetic Alterations in Animal Models of Parkinson's Disease.

Avila-Luna A, Verduzco-Mendoza A, Olmos-Hernandez A, Cortes-Altamirano J, Alfaro-Rodriguez A, Arias-Montano J Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770568 PMC: 11679969. DOI: 10.3390/ph17121726.


Striatal cell-type-specific molecular signatures reveal therapeutic targets in a model of dystonia.

Roman K, Dinasarapu A, Cherian S, Fan X, Donsante Y, Aravind N bioRxiv. 2024; .

PMID: 39415987 PMC: 11482807. DOI: 10.1101/2024.10.07.617010.


Targeting serum response factor (SRF) deactivates ΔFosB and mitigates Levodopa-induced dyskinesia in a mouse model of Parkinson's disease.

Kambey P, Wu J, Liu W, Su M, Buberwa W, Tang C Gene Ther. 2024; 31(11-12):614-624.

PMID: 39384937 DOI: 10.1038/s41434-024-00492-8.


Differential Activation States of Direct Pathway Striatal Output Neurons during l-DOPA-Induced Dyskinesia Development.

Figge D, Amaral H, Crim J, Cowell R, Standaert D, Eskow Jaunarajs K J Neurosci. 2024; 44(26).

PMID: 38664012 PMC: 11211726. DOI: 10.1523/JNEUROSCI.0050-24.2024.


Continuous long-range measurement of tonic dopamine with advanced FSCV for pharmacodynamic analysis of levodopa-induced dyskinesia in Parkinson's disease.

Park J, Kang S, Lee Y, Choi J, Oh Y Front Bioeng Biotechnol. 2024; 12:1335474.

PMID: 38328444 PMC: 10847580. DOI: 10.3389/fbioe.2024.1335474.